Substantial evidence shows that the safety profile of CRESTOR is in line with other marketed statins
A substantial and growing body of evidence form our market leading safety monitoring programme for statins, has clearly shown that the safety profile of CRESTOR is in line with other marketed statins.
Additionally as CRESTOR is not metabolised by the CYP450 3A4 pathway it has a lower potential for drug interactions.
The overall safety programme consists of three elements:
- Controlled clinical trial data
- Post marketing surveillance in over 11 million patients worldwide
- Controlled pharmacoepidemiology data conducted in four markets
Page tools
Publication updates
Register for the alert service and receive updates when
publications onrosuvastatin are published.
Efficacy
Clinical research
The best surrogate data will translate into the best clinical outcomes seen so far with statin
therapy.